Baker Bros. Advisors Adds $9M in Alumis Inc. ($ALMS)

Key Points

  • Baker Bros. Advisors changed its Alumis Inc. ($ALMS) stake by 28.80% last quarter, boosting to 2,012,500 shares worth $42.32 million.
  • Wall Street's consensus rating on $ALMS is Strong Buy and an average price target of $40.33.
  • $ALMS last traded around $21.03.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Baker Bros. Advisors increased its position in Alumis Inc. ($ALMS) by 28.80% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,012,500 shares of Alumis Inc. after buying 450,000 shares during the quarter. Baker Bros. Advisors's holdings in Alumis Inc. were worth $42.32 million as of its most recent filing.

Alumis Inc. Stock Down 6.0%

Shares of Alumis Inc. ($ALMS) traded around $21.03 on Saturday, down 6.0% for the day.

Last price$21.03
Market cap$2.82B
Forward P/E-7.61
Beta-0.67
52-week low$3.76
52-week high$31.35
50-day MA$26.49
200-day MA$22.01
Current ratio6.74
Quick ratio6.64
Debt-to-equity0.08

Alumis Inc. Earnings

EPS (ttm)-$4.11
Revenue (ttm)$7.40M
Revenue growth-37.70%
Net margin0%
Return on equity-93.65%
Next earningsNov 12, 2026

Analysts Set New Price Targets

ConsensusStrong Buy
Average target$40.33
High target$55
Low target$25
Analysts covering9

About Alumis Inc.

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

ExchangeNasdaqGS
SectorHealthcare
IndustryBiotechnology
HeadquartersSouth San Francisco, CA
CEOMr. Martin Babler Ph.D.
Employees237

Get Alumis Inc. alerts

New 13F filings, insider trades, and analyst moves on $ALMS, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.